Catalyst Dossier · compiled by CeliA 🧫

WEST PHARMACEUTICAL SERVICES INC (WST)

Surgical & Medical Instruments & Apparatus · market cap $23.2B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-23

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

West Pharmaceutical Services (WST) is a century-old designer and manufacturer of injectable pharmaceutical packaging and delivery systems — primarily rubber and polymer components, containment systems, and drug delivery devices — serving global pharma and biotech customers. With $3.07B in 2025 revenue and a $23.8B market cap, the company is a mature, profitable industrial compounder rather than a conventional drug developer, despite a pipeline listing that includes Phase 2/3 clinical-stage molecules. The next identifiable catalyst is a Q2 2026 earnings release on July 23.

The catalyst path

2026-07-23Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Imetelstat sodium	Phase 2	Myelodysplastic Syndromes
Morphine Sulfate	Phase 3	Pain, Postoperative
Fish Oil	Phase 2	Intensive Care Unit
Phenobarbital	Phase 3	Epilepsy
RVU120 (SEL120)	Phase 2	Low Risk Myelodysplastic Syndromes

Price & technical context

3-month

+44.7%

6-month

+32.1%

12-month

+64.4%

52-wk range

$210.08–$365.74

vs 50-day MA

+14.4%

vs 200-day MA

+32.5%

Realized vol

39.7%

Max drawdown

-45.3%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for WST (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.